Belite Bio Announces Pricing of $30 Million Underwritten Public Offering of American Depositary Shares and Warrants
The gross proceeds of the offering to the Company are expected to be $30 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Belite Bio, and excluding the exercise of any warrants.
- The gross proceeds of the offering to the Company are expected to be $30 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Belite Bio, and excluding the exercise of any warrants.
- All of the securities in the offering are to be sold by Belite Bio.
- The closing of the offering is expected to occur on or about June 2, 2023, subject to the satisfaction of customary closing conditions.
- SVB Securities LLC, Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC are acting as joint book-running managers for the offering.